What FDA’s 2026 Warning Letters to “Research Peptide” Sellers Actually Say
FDA warned five research-peptide sellers on Aug 24, 2026. We read all seven 2026 letters: what they named, why the label failed, and what it means for you.
Home › Research
Research Library: Long-Form Analysis, Every Figure Dated
Released: ·Last reviewed: ·Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
17 long-form analyses. Each is built on named trials, published price guides and regulator statements, with the date each source was read on the page. Newest: October 15, 2026.
NAD+, Glutathione, MIC-B12 and Vitamin Shots: What FDA Allows and What Clinics Charge
NAD+, glutathione, MIC-B12 and vitamin shots, Oct 2026: which FDA lists they are on, what is approved, what 4 telehealth clinics charge, and what to check.
The GLP-1 Patent Cliff: Why a Generic Arrives in Canada Before the United States
Semaglutide's foundational patent expired 20 March 2026 in India, China, Brazil and South Africa and lapsed in Canada. US protection runs to at least 2032. The dates, market by market.
Peptides, Ranked by Evidence: What Has a Phase 3 Trial and What Has a Forum Post
BPC-157, TB-500, ipamorelin, sermorelin, tesamorelin and the GLP-1s sit at wildly different evidence levels. A tiered map of what each actually has behind it.
GLP-1 Cost by State in 2026: Medicaid Coverage, Mandates and What You Actually Pay
Medicaid coverage of GLP-1s for obesity varies by state, and a state with no coverage changes the cheapest route entirely. Coverage type, cash routes and what to ask, state by state.
Rybelsus, Ozempic and Wegovy: One Molecule, Three Products, Three Different Answers
All three contain semaglutide. They differ in approved indication, maximum dose, route and price — and those differences decide coverage more than the molecule does.
How to Verify a GLP-1 Provider in Five Minutes, Using Only Primary Sources
Five free public databases settle whether a telehealth provider and its pharmacy are what they say. The checks, in order, and what each one can and cannot tell you.
What Happens When You Stop a GLP-1: The Withdrawal Data, Trial by Trial
STEP-1 reported about two-thirds of lost weight returned within a year of stopping. SURMOUNT-4 reported regain on withdrawal against continued loss on treatment. The numbers, and what they mean.
NovoCare Pharmacy Pricing in 2026: Every Dose, Every Condition, Every Expiry Date
The manufacturer's direct self-pay channel, read from its own price guide: $149 to $499 depending on product and dose, with two rates that expire on stated dates.
The Advertised Price Is Not the Price: Membership Fees, Dose Tiers and Prepay Traps
Four pricing structures separate an advertised monthly figure from what lands on your card. How each works, and the four questions that surface all of them.
The Legal Status of Compounded GLP-1s in 2026: What Actually Changed
The FDA declared the semaglutide shortage resolved in February 2025. That ended the mass-compounding pathway. What remains is 503A patient-specific compounding, and it requires a documented reason.
Liraglutide Has Two FDA-Approved Generics. Here Is Why It Is Still Not the Obvious Choice
Generic liraglutide referencing Victoza arrived in December 2024 and Saxenda in August 2025. It is the cheapest approved GLP-1 — and it produced 6.4% against semaglutide's 15.8% head to head.
GLP-1s and Muscle Mass: What the Body-Composition Sub-Studies Actually Found
A share of weight lost on any effective intervention is lean mass. What the imaging sub-studies reported, what they could not measure, and why no protocol is evidence-based yet.
GLP-1 Side Effects Week by Week: When Nausea Peaks and When It Resolves
Gastrointestinal effects cluster at dose increases rather than spreading evenly. What the trials reported, when discontinuation happens, and what the label says about the titration schedule.
Tesamorelin (Egrifta): The One Growth-Hormone Peptide With an Approved Indication
Approved for HIV-associated lipodystrophy, not for general fat loss or anti-ageing. What the trials established, the labelled risks, and why it is not comparable to a GLP-1.
GLP-1s and Surgery: The Fasting Guidance That Changed, and Why It Matters
Delayed gastric emptying means a standard pre-operative fast may not empty the stomach. What anaesthesia guidance says, and why it applies to compounded products too.
Who Should Not Take a GLP-1: Contraindications, Cautions and the Boxed Warning
A boxed warning, absolute contraindications and several situations requiring caution. What the labelling states and what an online intake should be asking you.